Analysts forecast that Ionis Pharmaceuticals Inc (NASDAQ:IONS) will post earnings per share (EPS) of $1.20 for the current quarter, Zacks reports. Six analysts have made estimates for Ionis Pharmaceuticals’ earnings. The lowest EPS estimate is $0.88 and the highest is $1.39. Ionis Pharmaceuticals posted earnings per share of $2.42 during the same quarter last year, which would indicate a negative year over year growth rate of 50.4%. The company is scheduled to announce its next quarterly earnings report on Wednesday, February 26th.

On average, analysts expect that Ionis Pharmaceuticals will report full-year earnings of $1.99 per share for the current financial year, with EPS estimates ranging from $1.60 to $2.17. For the next financial year, analysts forecast that the business will report earnings of $0.21 per share, with EPS estimates ranging from ($1.43) to $1.08. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow Ionis Pharmaceuticals.

Ionis Pharmaceuticals (NASDAQ:IONS) last issued its earnings results on Wednesday, November 6th. The company reported $0.18 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.31) by $0.49. Ionis Pharmaceuticals had a return on equity of 36.31% and a net margin of 52.26%. The company had revenue of $168.00 million during the quarter, compared to the consensus estimate of $152.47 million. During the same period in the previous year, the company posted ($0.03) EPS. The firm’s revenue for the quarter was up 15.9% compared to the same quarter last year.

Several research firms recently weighed in on IONS. Needham & Company LLC reissued a “buy” rating and set a $87.00 price target on shares of Ionis Pharmaceuticals in a report on Thursday, November 7th. TheStreet cut Ionis Pharmaceuticals from a “b-” rating to a “c” rating in a report on Thursday, August 8th. Morgan Stanley cut Ionis Pharmaceuticals from an “equal” rating to a “weight” rating and dropped their price target for the stock from $63.00 to $48.00 in a report on Thursday, November 7th. Bank of America began coverage on Ionis Pharmaceuticals in a report on Wednesday, November 13th. They set a “buy” rating and a $70.00 price target for the company. Finally, Wells Fargo & Co lifted their price target on Ionis Pharmaceuticals from $90.00 to $120.00 and gave the stock an “outperform” rating in a report on Thursday, October 10th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $73.67.

In other Ionis Pharmaceuticals news, CFO Elizabeth L. Hougen sold 4,000 shares of Ionis Pharmaceuticals stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $58.80, for a total value of $235,200.00. Following the completion of the transaction, the chief financial officer now directly owns 24,055 shares of the company’s stock, valued at approximately $1,414,434. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Joseph Klein III sold 2,000 shares of Ionis Pharmaceuticals stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $60.00, for a total value of $120,000.00. Following the completion of the transaction, the director now directly owns 13,495 shares of the company’s stock, valued at $809,700. The disclosure for this sale can be found here. Over the last three months, insiders have sold 11,776 shares of company stock valued at $701,818. 2.40% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Benjamin F. Edwards & Company Inc. acquired a new position in Ionis Pharmaceuticals in the 3rd quarter valued at $125,000. Creative Planning grew its holdings in Ionis Pharmaceuticals by 2.4% during the 3rd quarter. Creative Planning now owns 23,285 shares of the company’s stock worth $1,395,000 after acquiring an additional 552 shares in the last quarter. IFM Investors Pty Ltd grew its holdings in Ionis Pharmaceuticals by 46.0% during the 3rd quarter. IFM Investors Pty Ltd now owns 12,234 shares of the company’s stock worth $733,000 after acquiring an additional 3,854 shares in the last quarter. California Public Employees Retirement System grew its holdings in Ionis Pharmaceuticals by 34.1% during the 3rd quarter. California Public Employees Retirement System now owns 291,371 shares of the company’s stock worth $17,456,000 after acquiring an additional 74,015 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. grew its holdings in Ionis Pharmaceuticals by 7.5% during the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 865,463 shares of the company’s stock worth $51,850,000 after acquiring an additional 60,363 shares in the last quarter. 87.27% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ IONS traded up $0.69 during midday trading on Friday, hitting $60.38. 961,000 shares of the company’s stock were exchanged, compared to its average volume of 1,138,906. The company has a quick ratio of 10.31, a current ratio of 10.39 and a debt-to-equity ratio of 0.44. Ionis Pharmaceuticals has a 12 month low of $48.27 and a 12 month high of $86.58. The company’s 50 day moving average price is $57.45 and its 200 day moving average price is $63.39. The firm has a market capitalization of $8.24 billion, a PE ratio of 20.40, a price-to-earnings-growth ratio of 2.27 and a beta of 1.90.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

See Also: LIBOR

Get a free copy of the Zacks research report on Ionis Pharmaceuticals (IONS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.